Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: Pilot study

Journal of Clinical Psychopharmacology

Volumn 23, Issue 5, 2003, Pages 479-483

  Wallaschofski, Henri ^a   Eigenthaler, Martin ^b   Kiefer, Markus ^c   Donné, Manfred ^c   Hentschel, Betina ^c   Gertz, Herman J ^c   Lohmann, Tobias ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PADGEM PROTEIN; PROLACTIN; THROMBIN RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HYPERPROLACTINEMIA; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET ACTIVATION; RISK FACTORS; STATISTICS, NONPARAMETRIC; THROMBOEMBOLISM;

EID: 0141593930     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000088914.24613.51     Document Type: Article

References (10)

1. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet. 2000;365:1219-1223.
2. Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol. 1988;27:272-275.
3. Orr MW, Boullin DJ. The relationship between changes in 5-HAT induced aggregation and clinical state in patients treated with fluphenazine. Br J Clin Pharmacol. 1976;3:925-928.
4. Li N, Hu H, Lindqvist M, et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol. 2000;20:2702-2708.
5. Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation. 2000;102:1931-1936.
6. Wallaschofski H, Donné M, Eigenthaler M, et al. Prolactin as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab. 2001;86:5912-5919.
7. Wallaschofski H, Kobser A, Koksch M, et al. Prolactin receptor signalling during platelet activation. Horm Metab Res. 2003;35:228-235.
8. Wahba A, Black G, Koksch M. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass. Thromb Haemost. 1996;75:844-848.
9. Pulmonary embolism prevention trial prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet. 2000;355:1295-1302.
10. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull. 2002;36:143-164.